Lamivudin in the treatment of chronic hepatitis B - A retrospective analysis in German centers;Retrospektive kohortenstudie zur lamivudintherapie bei patienten mit chronischer hepatitis B

Deutsche Medizinische Wochenschrift

Volumn 126, Issue 5, 2001, Pages 97-102

  Teuber, G ^a   Lohr H F ^b   Kallinowski, B ^c   Berg, T ^d   Muller R ^e   Zeuzem, S ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Heart Center Siegburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; FAMCICLOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 12; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; SKIN TOXICITY;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; EUROPE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 0035793303     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-10880     Document Type: Article

References (35)

1. Hepatitis B unable to secret e antigen and response to interferon in chronic hepatitis B
2. Long-term effect of interferon therapy in chronic hepatitis B
3. Enhanced HBeAg seroconversion rates in chinese patients on lamivudine
4. Incremental increases in HBeAg seroconversion and continued ALT normalisation in asian chronic HBV (CHB) patients treated with Lamivudin
5. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
6. Pretherapy alanine transaminase level as determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
7. Classification of chronic hepatitis. Diagnosis, grading and staging
8. A preliminary trial of lamivudine for chronic hepatitis B
9. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
10. Lamivudine as initial treatment for chronic hepatitis B in the United States
11. Efficacy of long-term lamivudine therapy in HBeAg negative chronic hepatitis B
12. A randomised controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg
13. Hepatitis B reactivation after lamivudine
14. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: Evidence of continuing viral suppression with longer duration and higher dose of lamivudine
15. Lamivudine. A review of its therapeutic potential in chronic hepatitis B
16. Long-term remission of chronic hepatitis B after alpha-interferon therapy
17. A one-year trial of lamivudine for chronic hepatitis B
18. Lamivudine is effective in suppressing hepatitis B virus DNA in chinese hepatitis B surface antigen carriers: A placebo controlled trial
19. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa
20. Three year lamivudine therapy in chronic HBV
21. Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multicenter study in asia
22. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
23. Long-term follow-up of chronic hepatitis B patients treated with interferon-alfa
24. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study
25. Lamivudine therapy for chronic hepatitis B: A six month randomized dose-ranging study
26. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamp vudine treatment
27. Therapy with nucleoside analogues for hepatitis B virus infection
28. Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB)
29. Seroconversion after lamivudine treatment is not durable in chronic hepatitis B
30. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
31. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
32. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B
33. Long-term follow-up of patients with chronic hepatitis B after interferon treatment
34. Interferon treatment in patients with chronic hepatitis B. A meta-analysis of the published literature
35. Effect of alpha-interferon treatment in patients with chronic hepatitis B: A metaanalysis